MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results Independent Data Safety Monitoring Board (DSMB) reviewing the Phase 3 ARES trial evaluating MaaT013 in aGvHD concluded on a positive benefit/risk ratio based on a good safety profile and positive preliminary efficacy results with an Overall Response Rate higher than pre-defined protocol assumptions [...]
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT PHOEBUS is a Phase 2b randomized placebo-controlled trial investigating MaaT033 as an adjunctive therapy to improve 12-month overall survival rates for allogeneic hematopoietic stem cell transplant (allo-HSCT) patients MaaT033, the Company’s second drug candidate, is a donor-derived [...]
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference Poster 1 presents Early Access Program (EAP) data for 111 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013. Poster 2 details the Phase 2b randomized, double-blinded study evaluating MaaT033 to enhance overall survival in allogenic hematopoietic cell transplantation patients. [...]
MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies Presentation of AI-based screening strategy developed to identify a new generation of drug candidates, MaaT034 being the first product from the new range. First-time presentation of in vitro data for MaaT034, a new generation [...]
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013 The independent Data Safety Monitoring Board (DSMB), after careful review of safety, efficacy, and protocol adherence, has unanimously recommended that the trial continues without modification. The DSMB concluded on a positive benefit/risk ratio based [...]
MaaT Pharma Announces Poster Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Two posters selected for non-clinical data presentation at leading immuno-oncology conference for the Company’s new drug candidate generation, MaaT03X, in combination with Immune Checkpoint Inhibitors (ICIs), for the first time. Lyon, France, September 27th, 2023 – 6:00 [...]
MaaT Pharma and Skyepharma Complete Construction of Europe's Largest Manufacturing Facility for Microbiome Ecosystem Therapies Major milestone achieved with new state-of-the-art microbiome facility spanning over 17,200 sq ft, completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe MaaT Pharma is Skyepharma’s Skyehub Bioproduction® first resident company [...]
MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results Independent Data Safety Monitoring Board (DSMB) reviewing the Phase 3 ARES trial evaluating MaaT013 in aGvHD concluded on a positive benefit/risk ratio based on a good safety profile and positive preliminary efficacy results with an Overall Response Rate higher than pre-defined protocol assumptions [...] 